Back to top
more

GSK PLC Sponsored ADR (GSK)

(Real Time Quote from BATS)

$41.21 USD

41.21
2,363,250

+0.89 (2.21%)

Updated Aug 13, 2024 03:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Lilly and Glaxo

The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Lilly and Glaxo

Emergent (EBS) Up on '19 View, Posts Preliminary '18 Results

Emergent (EBS) provides preliminary results for 2018 and guidance for 2019. The results exceed estimates.

Crowded Cancer Space Triggers Big M&A Deals: More in Store?

Following two blockbuster merger and acquisition deals, a rise in M&A activity in the pharma space is likely led by consolidation in the cancer space.

Merck Buys NASH Candidate, Keytruda Wins 5 Approvals in Japan

Merck (MRK) exercises option to in-license an insulin sensitizer from NGM Biopharmaceuticals for NASH and type II diabetes. Its key drug Keytruda snaps up five new label expansion nods in Japan.

The Zacks Analyst Blog Highlights: Facebook, Wells Fargo, AT&T, Intel and Glaxo

The Zacks Analyst Blog Highlights: Facebook, Wells Fargo, AT&T, Intel and Glaxo

Mark Vickery headshot

Top Research Reports for Facebook, Wells Fargo & AT&T

Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Wells Fargo (WFC) and AT&T (T).

Novartis (NVS) Benefits From New Drugs & Key Acquisitions

Novartis (NVS) gets a boost from strong performance of new drugs. Strategic acquisitions to foray into promising areas has also boosted investor sentiment.

Emergent (EBS) Files Application for Emergency Use of NuThrax

Emergent (EBS) submits an application to the FDA for the emergency use of its anthrax vaccine candidate, NuThrax.

GlaxoSmithKline (GSK) Stock Moves -0.84%: What You Should Know

In the latest trading session, GlaxoSmithKline (GSK) closed at $37.58, marking a -0.84% move from the previous day.

Pharma Stock Roundup: GSK, PFE Ink Consumer Health JV, JNJ Hit by Talc Allegations

Glaxo (GSK) and Pfizer (PFE) agree to merge their consumer healthcare units into a new JV. J&J stock hit by reports alleging it of being aware of the presence of asbestos in baby powder.

Merck's sBLA for Keytruda in Lung Cancer Gets Extended Review

FDA extends review period for label expansion application for Merck's (MRK) Keytruda in first-line lung cancer by three months. A decision is now expected in April 2019.

Novartis (NVS) Offers to Buy French Gene Therapy Manufacturer

Novartis (NVS) looks to buy French company, CellforCure to expand manufacturing capacity for innovative cell and gene therapies.

Company News For Dec 20, 2018

Companies In The News Are: FDX,GIS,LLY,PFE,GSK

Glaxo, Pfizer to Merge Consumer Health Units, Form New JV

Glaxo (GSK) and Pfizer agree to merge their consumer healthcare units into a new joint venture (JV) with almost $13 billion in annual sales. Glaxo will eventually spin-off the joint venture.

Pharma Stock Roundup: Glaxo's TESARO Buyout & Horlicks Sale, ASH Cancer Data Updates

Glaxo (GSK) to buy TESARO and divest Horlicks brand to Unilever. ASH cancer presentations grab headilines.

Gilead's (GILD) Harvoni and Descovy Get Approval in China

Gilead's (GILD) HCV drug Harvoni and HIV cocktail therapy Descovy get approval in China.

GlaxoSmithKline (GSK) Stock Moves -0.7%: What You Should Know

In the latest trading session, GlaxoSmithKline (GSK) closed at $38.34, marking a -0.7% move from the previous day.

Gilead (GILD) Announces Data on CAR T Therapy Candidate

Gilead (GILD) announces data on chimeric antigen receptor T (CAR T) cell therapy candidate at the ASH for the treatment of patients with relapsed or refractory acute lymphoblastic leukemia.

Company News For Dec 4, 2018

Companies In The News Are: TSRO,GSK,TRCO,NXST,VNDA,GBT

Glaxo to Buy Zejula Maker TESARO for $5.1B, Stock Down 8%

Glaxo (GSK) announces definitive deal to buy TESARO.

TESARO Shares Rally on Glaxo's $5.1 Billion Buyout Offer

TESARO (TSRO) receives an acquisition offer from London-based pharma giant, Glaxo, valuing the company at $75 a share. Total value of the deal stands at $5.1 billion which includes acquisition of debt.

Glaxo to Sell India's Popular Horlicks Brand to Unilever

Glaxo (GSK) divests its Horlicks and other nutrition products in India to Unilever.

Indrajit Bandyopadhyay headshot

Key Pharma Players With HIV Focus Ahead of World Aids Day

We take a look at some of the major pharma companies in the HIV market that are developing drugs to address the life-threatening disease.

Merck (MRK) Receives Approval for 2 HIV Medicines in EU

Merck's (MRK) two new HIV drugs, Pifeltro and Delstrigo, containing doravirine, get approval in EU.

Kinjel Shah headshot

4 Big Pharma Stocks to Add to Your Portfolio in December

The large-cap pharma industry has been on a strong footing lately. Here are four stocks from the space that investors may consider betting on.